Oncolytic viral therapy has been explored widely as an option for glioma treatment but its effectiveness has remained limited. CCN1 is an extracellular matrix (ECM) protein elevated in cancer cells that modulates their adhesion and migration by binding cell surface receptors. In this study, we examined an hypothesized role for CCN1 in limiting the efficacy of oncolytic viral therapy for glioma, based on evidence of CCN1 induction that occurs in this setting. Strikingly, we found that exogenous CCN1 in glioma ECM orchestrated a cellular antiviral response that reduced viral replication and limited cytolytic efficacy. Gene expression profiling and real time PCR analysis revealed a significant induction of type-I interferon responsive genes in response to CCN1 exposure. This induction was accompanied by activation of the Jak/Stat signaling pathway, consistent with induction of an innate antiviral cellular response. Both effects were mediated by the binding of CCN1 to the cell surface integrin α6β1, activating its signaling and leading to rapid secretion of interferon-α, which was essential for the innate antiviral effect.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary brain tumor and despite aggressive therapy involving tumor resection, chemotherapy and radiation treatment, median survival of patients remains less than 15 months from diagnosis (1) . Oncolytic viruses (OVs) are biological therapeutics that selectively replicate in and kill tumor cells. These viruses have shown promising results in preclinical models (2) , and their safety and efficacy is currently being investigated in clinical trials. Despite these advances, the impact of changes in the tumor microenvironment on OV therapeutic efficacy has not been very well studied.
We have previously described a dose dependent and rapid induction of the secreted angiogenic inducer Cysteine rich 61 (CCN1) in the tumor microenvironment following OV therapy (3) . CCN1 is a member of the growth factor inducible immediate early family CCN, named as such for its first three members Cysteine rich 61, connective tissue growth factor (CTGF), and Nephroblastoma-overexpressed (Nov) (4) . It is a secreted protein which typically localizes in the extracellular matrix (ECM) and on the cell surface (5) , where it binds integrin receptors to modulate a variety of cellular functions including adhesion, migration, and proliferation (6) . In brain tumors CCN1 is overexpressed in 68% (27/40) of GBM specimens and in cell lines derived from high-grade gliomas (7) . Its increased expression in the mucosa of patients with colorectal cancer has also implicated it in "priming for carcinogenesis" (8) and its oncogenic potential is largely accredited to its activation of integrin-linked kinase-mediated βcatenin-TCF/LEF and AKT (9) .
Apart from its induction in glioma cells infected with herpes simplex virus-1 (HSV-1) derived OVs, CCN1 has also been found to be dysregulated in cells after infection with Coxsackievirus B3 (CVB3) and Adenovirus type 12 (Ad12), suggesting that it may play a role in 4 viral infection of mammalian cells (10) (11) . Here we evaluated the impact of CCN1 expression on OV efficacy. Our findings indicate that CCN1 limits OV replication and cytotoxicity due to its significant activation and enhancement of the innate antiviral type-I interferon (IFN) response in cells. Furthermore, our studies reveal that this IFN response is activated by CCN1 binding to integrin α 6 
MATERIALS & METHODS

Cells and Viruses.
Human LN229, U343, Gli36ΔEGFR-H2B-RFP, U251T2, and U251T3 glioma cell lines are maintained as described (3) . EGFR-transduced baby hamster kidney JiEGFR cells are maintained as described (12) . Tet-regulated CCN1 expressing clones Cy-1 and Cy-2 were established as described (13) . For radiation studies, cells were irradiated at 10gy, using RS-2000 Biological Irradiator. HSV-1-derived OVs, rHSVQ1, rHsvQ1-IE4/5-Luc, and ENVE, have been previously described (14-16).
Animals.
All animal experiments were performed in accordance with the Subcommittee on Research Animal Care of The Ohio State University guidelines. Six to eight week old female athymic nude mice were used for all studies.
For CCN1 effects on viral progeny, mice were implanted subcutaneously with 4x10 RT-PCR. RNA was isolated using RNeasy Mini Kit (Qiagen). For Quantitative Real-Time PCR, cDNA was made using Superscript First-Strand Synthesis System (Invitrogen). Real time continuous detection of PCR product was achieved using Sybr Green (Applied Biosystems).
GAPDH was used as an internal control. Primers were designed using the Primer Express Program (Applied Biosystems) (Supplementary Table S1 ).
Microarray.
Total RNA from Cy-1 cells incubated±dox for 24h was isolated using RNeasy Mini Kit (Qiagen). Samples were then submitted to The Ohio State University Microarray Shared
Resource Center for microarray analysis using the Affymetrix GeneChip Analysis. The microarray data from this publication have been submitted to the GEO database (accession number GSE29384).
Statistical Analysis. Results are presented as mean values±standard error of the mean (SEM).
Statistical analysis was carried out by unpaired Student's t-test using GraphPad Prism ® 5.01 software. P values <0.05 were considered statistically significant. Affymetrix GeneChip was used for gene expression study. Signal intensities were quantified by Affymetrix software.
RESULTS
CCN1 gene expression is upregulated by virus but not by chemotherapy or radiation treatment
Apart from increased CCN1 gene expression in glioma cells post OV infection, its induction has also been described in H19-7 cells after treatment with etoposide, in UV irradiated human skin fibroblasts, and in HeLa cells infected with Coxsackievirus B3 virus (10, (18) (19) . 
CCN1 mediated OV inhibition is dependent on α 6 β 1 integrin receptor-mediated IFNα secretion
CCN1 is a multifunctional, secreted ECM protein that has been shown to bind to multiple cell surface receptors including integrins α v β 3 , α v β 5 , and α 6 β 1 . In order to determine the cell surface receptor through which CCN1 is mediating its antiviral effects, we investigated the potential contribution of these receptors. We first evaluated the ability of cRGD (Cilengitide; α v β 3 antagonist) and LM609 (a function-blocking monoclonal antibody against α v β 3 ) to rescue virus inhibition in dox induced Cy-1 cells. Figures 6A-B show that neither agent could rescue CCN1 mediated OV repression. Consistent with this result, LN229 glioma cells plated on fibronectin coated plates (a known αvβ3 activating ligand) also had no effect on OV transgene expression ( Figure 6C ).
We next assessed the potential role of integrin α v β 5 in CCN1 mediated OV inhibition. CCN1's role in tumor biology has been extensively studied, and depending on the tissue type has been found both pro-and anti-tumorigenic (36). Apart from negatively modulating the cellular response to OV therapy, the expression of CCN1 protein in breast, prostate, and ovarian cancer correlates with a poor prognosis (37-39). Conversely, its expression in lung, endometrial, and gastric cancer has been associated with a better prognosis and outcome (40) (41) (42) . Though the reason underpinning CCN1's opposing effect in different tissue has not been elucidated, it may depend in part on the context in which CCN1 is expressed differing by the presence of coactivators and repressors, and the receptor expression profiles present in different tissues. Here we show that CCN1 activates a type-I IFN pro-inflammatory cascade in glioma cells by binding to and activating the α 6 β 1 integrin receptor and inducing secretion of IFNα. We show that CCN1 expression not only upregulates the type-I IFNs α and β, but also several downstream mediators of the type-I IFN response known to play key roles in the cellular antiviral defense response such as PKR and OAS (43) (44) . These results suggest that while expression of CCN1 leads to increased angiogenesis and invasion in the tumors, it also interferes with oncolytic viral therapy and inhibition of this pathway may provide opportunities to enhance OV anti-tumor efficacy.
Recently, integrin α 6 has been recognized as an enrichment marker for glioblastoma stem cells (GSCs) (26), and was found to be coexpressed with CD133 (a widely accepted glioma stem cell marker) in GBM biopsies. Apart from increased tumorigenicity, glioma stem cells have been shown resistant to both radiation and chemotherapy (45) . In U87 glioma cells, it has been shown that stable cell surface expression of integrin α 6 β 1 leads to both enhanced proliferation and decreased apoptosis in vitro and in vivo (46) . The results from our study indicate that CCN1 mediated activation of integrin α 6 contributes to the reduced efficacy of viral oncolytic therapy and it will be interesting to understand how the CCN1-integrin α 6 interaction plays a role in glioma therapeutic resistance.
In conclusion, this is the first study to reveal the effect of a secreted matricellular integrin binding protein on the initiation of an innate type-I IFN cellular defense response to virus infection. This study suggests that therapeutic interventions which inhibit the CCN1-integrin α 6 interaction may sensitize glioma to chemo and radiation therapies and viral oncolysis. Future studies will evaluate the extent to which expression of CCN1 and/or integrin α 6 receptor on tumors can serve as a predictor of patient response to oncolytic viral therapy. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha (6)beta (1) 
